» Articles » PMID: 1637678

Reversal of Multidrug Resistance by Surfactants

Overview
Journal Br J Cancer
Specialty Oncology
Date 1992 Jul 1
PMID 1637678
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Cremophor EL, a pharmacologically inactive solubilising agent, has been shown to reverse multidrug resistance (MDR). Using flow cytometric evaluation of equilibrium intracellular levels of daunorubicin (DNR), we found that eight other surface active agents will also reverse MDR. All the active detergents contain polyethoxylated moieties but have no similarities in their hydrophobic components. The properties of three polyethoxylated surfactants that showed the lowest toxicities, Cremophor, Tween 80 and Solutol HS15, were examined in more detail. The concentrations of Tween 80 and Solutol required to reverse DNR exclusion were 10-fold lower than for Cremophor. However while concentrations greater than or equal to 1:10(2) of the former two surfactants resulted in breakdown of cells, even 1:10 of Cremophor did not lyse cells. Studies of the effects of Cremophor on the uptake and efflux of DNR in normal and MDR cell types showed that Cremophor increases intracellular DNR primarily by locking the rapid efflux from the cells. This blockage of drug efflux may be mediated by a substantial alteration in the fluidity of cell membranes induced by Cremophor, as shown by decreased fluorescence anisotropy of a membrane probe. Consistent with these data, coinjection of adriamycin plus Cremophor into mice carrying a multidrug resistant P388 transplantable tumour significantly increased the survival time of the mice compared with adriamycin treatment alone.

Citing Articles

The complex relationship between multiple drug resistance and the tumor pH gradient: a review.

Koltai T Cancer Drug Resist. 2022; 5(2):277-303.

PMID: 35800371 PMC: 9255250. DOI: 10.20517/cdr.2021.134.


Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models.

Zheng Q, Zhang B, Li C, Zhang X Front Oncol. 2022; 12:850732.

PMID: 35372014 PMC: 8970309. DOI: 10.3389/fonc.2022.850732.


Non-ionic Surfactants as a P-Glycoprotein(P-gp) Efflux Inhibitor for Optimal Drug Delivery-A Concise Outlook.

Rathod S, Desai H, Patil R, Sarolia J AAPS PharmSciTech. 2022; 23(1):55.

PMID: 35043278 DOI: 10.1208/s12249-022-02211-1.


Effects of co-formulants on the absorption and secretion of active substances in plant protection products in vitro.

Karaca M, Fischer B, Willenbockel C, Tralau T, Marx-Stoelting P, Bloch D Arch Toxicol. 2021; 95(10):3205-3221.

PMID: 34417632 PMC: 8448693. DOI: 10.1007/s00204-021-03140-x.


Excipient knowledgebase: Development of a comprehensive tool for understanding the disposition and interaction potential of common excipients.

McFeely S, Yu J, Wang Y, Wu C, Ragueneau-Majlessi I CPT Pharmacometrics Syst Pharmacol. 2021; 10(8):953-961.

PMID: 34102029 PMC: 8376134. DOI: 10.1002/psp4.12668.


References
1.
Kakehi Y, Kanamaru H, Yoshida O, Ohkubo H, Nakanishi S, Gottesman M . Measurement of multidrug-resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol. 1988; 139(4):862-5. DOI: 10.1016/s0022-5347(17)42663-2. View

2.
Moscow J, Cowan K . Multidrug resistance. J Natl Cancer Inst. 1988; 80(1):14-20. DOI: 10.1093/jnci/80.1.14. View

3.
FRANKFURT O . Flow cytometric screening for selective toxicity to multidrug-resistant cells. J Natl Cancer Inst. 1987; 79(4):831-6. View

4.
Fojo A, Shen D, Mickley L, Pastan I, Gottesman M . Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol. 1987; 5(12):1922-7. DOI: 10.1200/JCO.1987.5.12.1922. View

5.
Woodcock D, JEFFERSON S, Linsenmeyer M, Crowther P, Chojnowski G, Williams B . Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res. 1990; 50(14):4199-203. View